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Background. CD97 as a member of the EGF-TM7 family with adhesive properties plays an important role in tumor aggressiveness
by binding its cellular ligand CD55, which is a complement regulatory protein expressed by cells to protect them from bystander
complement attack. Previous studies have shown that CD97 and CD55 both play important roles in tumor dediﬀerentiation,
migration,invasiveness,andmetastasis.TheaimofthisstudywastoinvestigateCD97andCD55expressioninprimarygallbladder
carcinoma (GBC) and their prognostic signiﬁcance. Methods. Immunohistochemistry was used to investigate the expression of
CD97 and CD55 proteins in 138 patients with GBC. Results. CD97 and CD55 were absent or only weakly expressed in the normal
epithelium of the gallbladder but in 69.6% (96/138) and 65.2% (90/138) of GBC, respectively, remarkably at the invasive front
of the tumors. In addition, CD97 and CD55 expressions were both signiﬁcantly associated with high histologic grade (both P =
0.009), advanced pathologic T stage (P = 0.01 and 0.009, resp.) and clinical stage (both P = 0.009), and positive venous/lymphatic
invasion (both P = 0.009). Multivariate analyses showed that CD97 (hazard ratio, 3.236; P = 0.02) and CD55 (hazard ratio,
3.209; P = 0.02) expressions and clinical stage (hazard ratio, 3.918; P = 0.01) were independent risk factor for overall survival.
Conclusion.OurresultsprovideconvincingevidencefortheﬁrsttimethattheexpressionsofCD97andCD55arebothupregulated
in human GBC. The expression levels of CD97 and CD55 in GBC were associated with the severity of the tumor. Furthermore,
CD97 and CD55 expressions were independent poor prognostic factors for overall survival in patients with GBC.
1.Introduction
Primarygallbladdercarcinoma(GBC)isthesixthmostcom-
mon gastrointestinal cancer in Asian and Western countries
[1]. This carcinoma has extremely poor prognosis and
increasing incidence worldwide because of its inherent
biology and often advanced stage at diagnosis, despite the
recent advances in diagnostic modalities. GBC has a great
propensity to directly invade the liver, and it also frequently
metastasizes to the liver and pericholedochal lymph nodes
[2]. There are no adjuvant chemotherapeutic combinations
widelyacceptedforGBCduetotheirtoxicity,drugresistance,
and limited eﬃcacy. Curative surgical approaches are still
the principal treatment, but the prognosis of GBC remains
poor with respect to postsurgical 5-year survival rates [3].
Thus, the search for new prognostic markers for GBC
patients is important to allow the assessment of metastasis
and to provide the opportunity for adequate postoperative
treatment in high-risk patients.
CD97 is a member of the epidermal-growth-factor
(EGF-)seven-spantransmembrane(TM7)familywithadhe-
sive properties [4]. This family includes EMR1, EMR2,
EMR3, ETL, and the mouse microglia marker F4/80, which
are characterized by an extended extracellular region with
a variable number of EGF domains. So far, CD97 is the
only EGF-TM7 family member of which a ligand has been
identiﬁed [5]. Via its EGF domain region, CD97 binds
CD55 (also named as decay accelerating factor, DAF), a
glycosylphosphatidylinositol-anchored protein, which regu-
lates complement activation pathway [6]. As in the case of
manyglycosylphosphatidylinositol-anchoredproteins,CD55
is either bound to the cell membrane or released from
the membrane into the microenvironment. CD55 binds
to C3 convertases generated from both the classic and2 Journal of Biomedicine and Biotechnology
alternative complement pathways, prevents C3b deposition,
thus inhibiting the formation of membrane attack complex.
Physiologically CD55 serves as an inhibitor of the comple-
ment system [7]. Various evidences showed that CD97 and
CD55 both play important roles in tumor dediﬀerentiation,
migration, invasiveness, and metastasis [8–12]. For example,
the expressions of CD97 and CD55 in rectal tumor tissues
were signiﬁcantly higher than those in normal colorectal
tissues. The patients with recurrence and/or metastasis had
signiﬁcantly higher expressions of CD97 in tumor cells and
CD55 in stroma at the invasion front than those patients
without recurrence and/or metastasis [8]. Durrant et al.
also demonstrated that the colorectal cancer patients whose
tumors overexpress CD55 have a signiﬁcantly reduced 7-year
survival [10]. The ﬁndings of Liu et al. suggest that CD97
may play a role in the development and invasion of gastric
carcinomas by binding its cellular ligand CD55. Detection of
the CD97 expression in the tumor margin could be referred
to as the molecular edge of gastric carcinomas. They also
suggested that CD97 and CD55 could be useful as molecular
markers for prognosis and therapy of gastric carcinoma
patients[11,12].However,theexpressionandclinicalimpact
of CD97 and its ligand CD55 in GBC have not been pre-
viously investigated. Herein, we found that the expressions
of CD97 and CD55 are both upregulated in human GBC.
Their expression levels in GBC were both associated with
the severity of the tumor. Furthermore, CD97 and CD55
expressions were independent poor prognostic factors for
overall survival in patients with GBC.
2.MaterialsandMethods
2.1. Patients and Tissue Samples. This study was approved
by the Research Ethics Committee of the Huai’an First
People’s Hospital Aﬃliated to Nanjin Medical University,
Huai’an, Jiangsu, China. Written informed consent was
obtainedfromallofthepatients.Allspecimenswerehandled
and made anonymous according to the ethical and legal
standards.
We retrospectively investigated 138 patients (60 men and
78 women) with GBC who underwent surgical resection
between March 1999 and January 2010 at Department of
Hepatobiliary Pancreatic Surgery, the Huai’an First People’s
Hospital Aﬃliated to Nanjin Medical University, Huai’an,
Jiangsu, China. No preoperative chemotherapy or radiother-
apy had been performed in any of these cases. Patients,
who died of diseases not directly related to their GBC or
due to unexpected events, were excluded from this study.
The mean age of the patients was 68 years (range, 36–
88 years). All tumors were diagnosed as adenocarcinoma
and deﬁned as primary tumor arising from the gallbladder.
Tumor stage was classiﬁed according to the American Joint
Committee on Cancer system. All protocols were approved
by the institutional review board. The GBC specimens were
examined by routine hematoxylin and eosin staining. The
specimens were graded into well (G1), moderately (G2),
poorly diﬀerentiated (G3), and undiﬀerentiated (G4) ade-
nocarcinoma according to the World Health Organization
classiﬁcation.
2.2. Immunohistochemistry Assay. Formalin-ﬁxed, paraﬃn-
embedded, sectioned tissues (4µm thick) were immunos-
tained using the Labelled Streptavidin Biotin 2 System
(BioGenex; San Ramon, CA, USA). Following peroxidase
blocking with 0.3% H2O2/methanol for 30min, specimens
were blocked with phosphate-buﬀered saline (PBS) con-
taining 5% normal horse serum (Vector Laboratories Inc.,
Burlingame, CA, USA). All specimens were incubated with
monoclonal antibodies against CD55 (clone 143-30, BD
Biosciences, Heidelberg, Germany) and CD97 (MEM180,
Biermann, Germany) at dilutions of 1:100, respectively,
overnight at 4◦C. Then the specimens were brieﬂy washed in
PBSandincubatedatroomtemperaturewiththeanti-mouse
antibody and avidin-biotin peroxidase (Vector Laboratories
Inc., Burlingame, CA, USA). The specimens were then
washed in PBS and color-developed by diaminobenzidine
solution (Dako Corporation, Carpinteria, CA, USA). After
washing with water, specimens were counterstained with
Meyer’s hematoxylin (Sigma Chemical Co., St. Louis, MO,
USA). Nonimmune IgG was used as negative control anti-
body for immunohistochemical staining.
Assessment of immunohistochemical staining was eval-
uated by two independent pathologists. The numbers of
CD97-positive and CD55-positive cells in 10 representative
microscopic ﬁelds were counted. The percentage of positive
cells was judged followed by Remmele W’s criteria [13]
ranging from 1 to 4 (1, <10%; 2, 10 to 50%; 3, 51 to 80%; 4,
>80%positivetumorcells),andthelevelofstainingintensity
wasestimatedtogradesbetween0and3(0,negative;1,weak;
2, moderate; 3, strong staining). The product of positive cells
and staining intensity gave the score (0 to 12). We considered
the samples positive if the score was higher than 4.
2.3. Statistical Analysis. All computations were carried out
using the software of SPSS version13.0 for Windows (SPSS
Inc., IL, USA). Categorical data were examined by use of the
chi-squared test. Overall survival (OS) was deﬁned from the
date of surgery to the date of death by GBC. Survival curves
were plotted using the Kaplan-Meier method and analyzed
using the log-rank test. Cox proportional hazards model
was performed to identify prognostic factors for survival.
Diﬀerences were considered statistically signiﬁcant when P
w a sl e s st h a n0 . 0 5 .
3. Results
3.1. Immunohistochemical Staining of CD97 and CD55 Pro-
teins in GBC Tissues. Our analysis determined that CD97
and CD55 were absent or only weakly expressed in the
normal epithelium of the gallbladder (Figures 1(A) and
1(B), resp.) but in 69.6% (96/138) and 65.2% (90/138) of
GBC, respectively, remarkably at the invasive front of the
tumors. The expression pattern of CD97 was signiﬁcantly
correlated with that of CD55 (r = 0.86, P = 0.002). CD97
immunoreactivity was observed in the cytoplasm of tumor
cells (Figures 1(C) and 1(D)), and CD55 immunoreactivity
was observed on the cell membrane of tumor cells (Figures
1(E) and 1(F)), both with varying levels of percentage tumor
staining and intensities.Journal of Biomedicine and Biotechnology 3
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Figure 1: Immunohistochemical stainings for CD97 and CD55 in GBC tissues (original magniﬁcation ×200). (A) and (B) CD97 and CD55
stainings were negative in nontumor brain tissues; (C) weak CD97 positive expression was found in the cytoplasm at various levels in GBC
tissues with low clinical stage; (D) strong CD97 positive expression was found in the cytoplasm at various levels in GBC tissues with high
clinical stage; (E) weak CD55 positive expression was found in the cell membrane at various levels in GBC tissues with low clinical stage; (F)
strong CD55 positive expression was found in the cell membrane at various levels in GBC tissues with high clinical stage.
3.2. Correlation of CD97 and CD55 Expression with Clinico-
pathologic Factors. We next analyze the correlation between
CD97 and CD55 expression and various clinicopathologic
factors that can aﬀect the prognosis of patients with GBC.
T h er e s u l t sa r es u m m a r i z e di nTable 1. There was no as-
sociation of the expression patterns of CD97 and CD55
with age and sex. Interestingly, the expression of CD97
a n dC D 5 5i nm o d e r a t e l yo rp o o r l yd i ﬀerentiated GBC was
signiﬁcantly higher than that in well-diﬀerentiated GBC
(both P = 0.009), indicating a correlation between their
expressions and aggressive histologic grade of GBC. In
addition, expression of CD97 and CD55 was also signiﬁ-
cantly associated with advanced pathologic T stage (P =
0.01 and 0.009, resp.), advanced clinical stage (both P =
0.009), and positive venous/lymphatic invasion (both P =
0.009). Other clinicopathologic factors such as lymph node
metastasis, distant metastasis, and perineural invasion were
not signiﬁcantly related to CD97 and CD55 expression.
3.3. Correlation of CD97 and CD55 Expression with Survival.
To further investigate the clinical usefulness of CD97 and
CD55 expression in GBC, we compared OS according to
various clinicopathologic factors including expression levels
of CD97 and CD55. Age and sex did not inﬂuence the
OS. However, patients with high histologic grade, advanced
pathologic T stage, clinical stage, nodal metastasis, positive
venous/lymphatic invasion, CD97, and CD55 expression
were signiﬁcantly correlated with short survival. The median
survival time of patients with GBC was 38 months (range,
1–119 months). The survival curves according to CD97
and CD55 expression are shown in Figures 2(a) and 2(b),
respectively. The OS rates of CD97 negative and CD97
positive were 42.9% and 12.5%, respectively (Figure 2(a))
(P = 0.02), and the OS rates of CD55 negative and CD55
positive were 45.8% and 17.8%, respectively (Figure 2(b))
(P = 0.02). These analyses with Kaplan-Meier method
clearly showed the signiﬁcant impact of CD97 and CD55
expression on clinical outcome.
To estimate the clinical signiﬁcance of various prognostic
factors that might inﬂuence survival, univariate analyses
were performed. As summarized in Table 2, advanced patho-
logic T stage (P = 0.008), advanced clinical stage (P =
0.001), nodal metastasis (P<0.001), distant metastasis (P =
0.001), positive venous/lymphatic invasion (P = 0.001),
positive perineural invasion (P = 0.01), positive CD97 (P =
0.005) and CD55 expression (P = 0.007), and the coex-
pression of CD97 and CD55 (P = 0.008) were statistically
signiﬁcant risk factors aﬀecting OS of patients with GBC.
To determine the independent prognostic impacts of these
various factors, multivariate analyses were performed using
the Cox proportional hazards model. Multivariate analyses
showed that CD97 (hazard ratio, 3.236; P = 0.02) and CD55
(hazard ratio, 3.209; P = 0.02) expressions, the coexpression
of CD97 and CD55 (P = 0.01), and clinical stage (hazard
ratio, 3.918; P = 0.01) were independent risk factors for
overall survival (Table 3). These results indicate that CD97
and CD55 expression might be potential histopathological
biomarkers to predict patient survival.4 Journal of Biomedicine and Biotechnology
Table 1: Correlation of CD97 and CD55 expressions with conventional clinicopathological parameters in 138 patients with GBC.
Factor Number
CD97 expression (n,% )
P
CD55 expression (n,% )
P
Negative Positive Negative Positive
Gender
Male 60 16 (26.7) 44 (73.3) NS 20 (33.3) 40 (66.7) NS
Female 78 26 (33.3) 52 (66.7) 28 (35.9) 50 (64.1)
Age at diagnosis 67.2 ±1.36 9 .7 ±1.8N S 6 7 .0 ±1.56 9 .8 ±1.9N S
Histological grade
G1 18 18 (100.0) 0 (0.0)
0.009
18 (100.0) 0 (0.0)
0.009 G2 84 23 (27.4) 61 (72.6) 26 (31.0) 58 (69.0)
G3 34 1 (2.9) 33 (97.1) 4 (11.8) 30 (88.2)
G4 2 0 (0.0) 2 (100.0) 0 (0.0) 2 (100.0)
Pathologic T stage
T1 32 23 (71.9) 9 (29.1)
0.01
25 (78.1) 7 (21.9)
0.009 T2 64 13 (20.3) 51 (79.7) 17 (26.6) 47 (73.4)
T3 36 6 (16.7) 30 (83.3) 6 (16.7) 30 (83.3)
T4 6 0 (0.0) 6 (100.0) 0 (0.0) 6 (100.0)
Clinical stage
I 60 30 (50.0) 30 (50.0)
0.009
35 (58.3) 25 (41.7)
0.009 II 48 10 (20.8) 38 (79.2) 11 (22.9) 37 (77.1)
III 18 2 (11.1) 16 (88.9) 2 (11.1) 16 (88.9)
IV 12 0 (0.0) 12 (100.0) 0 (0.0) 12 (100.0)
Nodal metastasis
Negative 102 31 (30.4) 71 (69.6) NS 35 (34.3) 67 (65.7) NS
Positive 36 11 (30.6) 25 (69.4) 13 (36.1) 23 (63.9)
Distant metastasis
Negative 126 38 (30.2) 88 (69.8) NS 43 (34.1) 83 (65.9) NS
Positive 12 4 (33.3) 8 (66.7) 5 (41.7) 7 (58.3)
Venous/lymphatic
invasion
Negative 48 28 (58.3) 20 (41.7) 0.009 28 (58.3) 20 (41.7) 0.009
Positive 90 14 (15.6) 76 (84.4) 20 (22.2) 70 (77.8)
Perineural invasion
Negative 66 26 (39.4) 40 (60.6) NS 22 (33.3) 44 (66.7) NS
Positive 72 24 (33.3) 48 (66.7) 26 (36.1) 46 (63.9)
Table 2: Univariate analysis of the associations of prognosis with various clinicopathologic parameters in patients with PGC.
Features
OS
HR 95% CI P
Gender 0.628 0.312–1.326 0.3
Age at diagnosis 0.696 0.383–1.508 0.2
Histological grade 33.291 0.869–1767.639 0.06
Pathologic T stage 2.923 1.385–8.763 0.008
Clinical stage 4.951 2.015–10.278 0.001
Nodal metastasis 3.009 1.172–8.638 <0.001
Distant metastasis 8.093 2.168–22.679 0.001
Venous/lymphatic invasion 11.662 2.908–51.338 0.001
Perineural invasion 3.921 1.087–8.692 0.01
CD97 expression 3.039 1.122–7.165 0.005
CD55 expression 2.763 0.928–6.927 0.007
CD97 positive/CD55 positive 2.591 0.882–6.626 0.008Journal of Biomedicine and Biotechnology 5
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Figure 2:CorrelationofCD97(a)andCD55(b)expressionwiththeoverallsurvivalratesin138patientswithGBC(comparedwithlog-rank
test).
Table 3: Multivariate analysis of the associations of prognosis with
various clinicopathologic parameters in patients with PGC.
Features
OS
HR 95% CI P
Pathologic T stage 0.202 0.007–5.109 0.4
Clinical stage 3.918 0.666–8.608 0.01
Nodal metastasis 1.058 0.532–3.596 0.7
Distant metastasis 1.926 0.512–4.053 0.6
Venous/lymphatic
invasion 1.851 0.512–4.106 0.6
Perineural invasion 0.662 0.228–1.986 0.4
CD97 expression 3.236 1.098–8.651 0.02
CD55 expression 3.209 0.993–8.625 0.02
CD97 positive/CD55
positive 4.027 0.696–8.881 0.01
4. Discussion
GBC is one of the most aggressive malignancies. It is usually
diagnosed at an advanced stage, and the prognosis remains
poor despite the improvement in imaging techniques and
aggressive surgical treatment. Therefore, identiﬁcation of
biologic markers associated with advanced stages of tumor
progression is necessary for early diagnosis and the discovery
ofatherapeutictarget.Toourknowledge,theidealcandidate
tumor markers must satisfy two criteria. First, it should be
selectively expressed solely on tumor cells, not surrounding
normal cells. Second, it should be speciﬁcally present and/or
overexpressed on various cancer tissues. There are three
main ﬁndings in the present study. At ﬁrst, strong CD97
and CD55 stainings were both observed at the invasive
tumor front but absent or weak in the normal epithelium
of the gallbladder. Then, CD97 and CD55 expression in
GBCwassigniﬁcantlycorrelatedwithtumorprogressionand
clinicopathologic features. Immunohistochemical analysis of
a large set of GBCs revealed that 69.6% and 65.2% of GBCs
were immunopositive for CD97 and CD55, respectively.
Their expressions in moderately or poorly diﬀerentiated
GBCweresigniﬁcantlyhigherthanthatinwell-diﬀerentiated
GBC. In addition, expression of CD97 and CD55 was
also signiﬁcantly associated with advanced pathologic T
stage, advanced clinical stage, and positive venous/lymphatic
invasion, suggesting that their expression might be of clinical
relevanceintheaggressivenessofGBC.Thirdly,theimpactof
CD97andCD55expressiononclinicaloutcomewasassessed
by Kaplan-Meier analyses. OS rates of CD97 negative and
CD55 negative were both signiﬁcantly higher than those of
CD97 positive and CD55 positive. Univariate and multi-
variate analyses clearly demonstrated that CD97 and CD55
expressions were statistically signiﬁcant risk factors aﬀecting
OS of patients with GBC and were independent risk factors
predicting short OS. These ﬁndings suggest that CD97 and
CD55 are ideal candidate tumor markers for GBC.
CD97 is a member of the EGF-7TM subfamily of class B
G-protein-coupledreceptors.Itconsistsofavariablenumber
of N-terminally located EGF domains, a long extracellular
stalk,the7-transmembranedomain,andashortintracellular
C-terminal region [14–16]. It has been demonstrated that
CD97 participates in the migration and invasion of tumor
cells, which can be strengthened by CD55, the ligand for
CD97 [17]. In gastric tumor tissues, the expression of CD55
was well correlated with that of CD97. Particularly, strong
staining of CD97 and CD55 was observed in the cytoplasm
of the signet ring cell carcinoma of patients, which suggests
that CD97 may be involved in the remodelling of adhesive
contacts of the invading tumor cells by direct receptor-ligand
interactions [18]. In colorectal carcinomas, CD97 and CD55
are overexpressed in the tumor environment. At the tumor-
stroma interface, CD97 is preferentially overexpressed in
tumor cells. By direct receptor-ligand interactions, CD97
may be involved in the remodeling of adhesive contacts6 Journal of Biomedicine and Biotechnology
of the invading tumor cells with the extracellular matrix.
In vitro colorectal tumor cell lines expressing CD55 and
endothelial cells deposit CD55 into the extracellular matrix.
Perhaps such exogenic signals from the speciﬁc tumor
environment regulate the cellular distribution of CD97 and
consequently activation of its unknown target genes [19]. In
medullary thyroid carcinomas, CD97 transcriptional activity
was high in advanced stages of tumor tissues such as pT3/4.
The pT1/2 tumors with exclusive intrathyroidal growth
revealed weak CD97 expression. CD55 gene expression was
signiﬁcantly lower in normal C-cells than in tumor tissues,
and all medullary thyroid carcinomas displayed strong and
speciﬁcCD55immunostaining[20].Inagreementwiththese
previous reports on other tumors, our study demonstrated
anoverexpressionofCD97andCD55inhumanGBCtissues,
which also correlated signiﬁcantly to the aggressive disease
features including high histologic grade, pathologic T stage,
clinical stage, positive venous/lymphatic invasion, and poor
postoperative prognosis. These ﬁndings suggest that the two
proteins may play an important role in tumor growth and
progressionofGBC.WhenitcomestotherelevanceofCD97
and CD55 to tumor treatment, Zhao et al. [21]r e p o r t e d
that CD55 may augment the therapeutic eﬀect of herceptin
against lung carcinoma cells; Geis et al. [22] indicated that
the inhibition of CD55 expression by siRNA could sensitize
tumor cells to complement attack in vitro; Dzietczenia et
al. [23] demonstrated that the CD55 expression in patients
with CD20+ non-Hodgkin’s lymphoma could be clinically
helpful to predict the response to rituximab therapy. The
involvement of CD97 and CD55 expression in the therapy
of GBC patients needs to be further investigated.
In conclusion, this preliminary study has demonstrated
for the ﬁrst time that CD97 and CD55 proteins might
be potential histopathological biomarkers for GBC. Their
expressionlevelsareassociatedwiththeseverityofGBC.Fur-
thermore, CD97 and CD55 expressions were independent
poor prognostic factors for overall survival in patients with
GBC.
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